Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000554864
Ethics application status
Approved
Date submitted
14/02/2012
Date registered
24/05/2012
Date last updated
24/05/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
Efficacy and acceptability of needles 4 mm length in pediatric insulin therapy
Scientific title
Pediatric patients affected by type 1 diabetes teaching to use 4 mm length needles for insulin therapy compared with diabetic children using 8 mm length needles regarding metabolic control parameters and quality of life
Secondary ID [1] 279720 0
Nil
Universal Trial Number (UTN)
U1111-1127-1444
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
type 1 diabetes 285556 0
risk of intramuscolar insulin injection 285557 0
Condition category
Condition code
Metabolic and Endocrine 285749 285749 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Use of 4 mm length needles for insulin administration for a period of 12 months, in newly type1 diabetic children or shift to 4 mm needles in patients undergoing therapy by 8 mm length needles; because the dosage of insulin should be adjusted according to blood glucose values, all patients are required to perform blood glucose testing at least 4 times/day and to apply a provided therapy algorithm
All patients and their parents will undergoing a 30 minutes instruction course, carried out by a trained nurse specialist, around the self-administration of insulin (if > 10 years old) or administration by parents (if < 10 years old), specifically aimed to the use of the needle of 4mm length
Intervention code [1] 284018 0
Treatment: Devices
Comparator / control treatment
Use of 8 mm length needles for insulin administration
Control group
Active

Outcomes
Primary outcome [1] 286296 0
average HbA1c from baseline, assessed by Siemens DCA Vantage Analizer
Timepoint [1] 286296 0
3,6,9, 12 months
Secondary outcome [1] 295558 0
Insulin/weight ratio, assessed on quarterly basis results of clinical examination and daily insulin requirements from glycemic diary
Timepoint [1] 295558 0
3, 6, 9, 12 months
Secondary outcome [2] 295559 0
Glycemic variability assessed by HBGI and LBGI evaluation of glucometer downloaded data (Accuchek SmartPix )
Timepoint [2] 295559 0
6, 12 months
Secondary outcome [3] 296092 0
Quality of life, assessed by Happy Face Rating Scale and Tuula-Maria Partanen questionnaire (Pract Diab Int april 2002 Vol. 19 No. 3)
Timepoint [3] 296092 0
6, 12 months

Eligibility
Key inclusion criteria
type 1 diabetes
Minimum age
2 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
coeliac disease, thyroiditis, psichiatryc impairment, coagulation disease; HbA1c > 9,5% (except time of diagnosis)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Therapy by 4 mm needles will be proposed to every newly diagnosed type 1 diabetes children treated at our regional centre and to all patients previously using 8 mm needles at periodic control time
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
na
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
1/04/2011
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment outside Australia
Country [1] 4051 0
Italy
State/province [1] 4051 0
Tuscany

Funding & Sponsors
Funding source category [1] 284522 0
Self funded/Unfunded
Name [1] 284522 0
Country [1] 284522 0
Italy
Primary sponsor type
Hospital
Name
AOU Meyer Children Hospital
Address
Viale Pieraccini 24 50139 Florence
Country
Italy
Secondary sponsor category [1] 283448 0
None
Name [1] 283448 0
Address [1] 283448 0
Country [1] 283448 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 286504 0
Meyer's Ethics Committee
Ethics committee address [1] 286504 0
Ethics committee country [1] 286504 0
Italy
Date submitted for ethics approval [1] 286504 0
Approval date [1] 286504 0
Ethics approval number [1] 286504 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33625 0
Address 33625 0
Country 33625 0
Phone 33625 0
Fax 33625 0
Email 33625 0
Contact person for public queries
Name 16872 0
Lenzi Lorenzo
Address 16872 0
Meyer Children Hospital, Viale Pieraccini 24, 50139 Florence
Country 16872 0
Italy
Phone 16872 0
+39 055 5662570
Fax 16872 0
+39 055 5662486
Email 16872 0
[email protected]
Contact person for scientific queries
Name 7800 0
Lenzi Lorenzo
Address 7800 0
Meyer Children Hospital, Viale Pieraccini 24, 50139 Florence
Country 7800 0
Italy
Phone 7800 0
+39 055 5662570
Fax 7800 0
+39 055 5662486
Email 7800 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.